WASHINGTON, April 18 /PRNewswire-FirstCall/ -- Novo Nordisk today announced the appointment of Dana Haza as Senior Director of the National Changing Diabetes Program.
(Photo: http://www.newscom.com/cgi-bin/prnh/20060418/PHTU019 )
(Logo: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGO )
The National Changing Diabetes Program was launched by Novo Nordisk at the end of 2005. The vision of the program is to change diabetes - to improve the lives of people impacted by this disease by causing change in the U.S. healthcare system to provide dramatic improvements in the prevention and care of diabetes.
“With over 15 years of healthcare experience combined with a strong policy background and understanding of the goals and the vision of the National Changing Diabetes Program, Dana has both the background and the passion to drive this effort - which will ultimately result in improved outcomes for the millions of Americans living with diabetes,” said Andrew Purcell, Vice President of Strategic Business Development.
As Senior Director of the National Changing Diabetes Program, Ms. Haza will lead the ongoing effort to galvanize all parties interested in preventing diabetes and advancing diabetes care in the U.S. Organizations supporting the goals of the National Changing Diabetes Program include the American Diabetes Association, the American College of Physicians, the American Association of Clinical Endocrinologists and the American Association of Diabetes Educators.
“Diabetes is a crisis in America. We cannot sit back and accept the fact that 1 in 3 of our nation’s children will develop diabetes in their lifetime,” said Ms. Haza. “The National Changing Diabetes Program will change that reality - and I am truly excited to be involved in an effort which will empower Americans to prevent or more effectively control diabetes.”
Most recently, Ms. Haza was with the U.S. Department of Health & Human Services (HHS) where she served as interim director of the Office of Programs and Coordination in the Office of the National Coordinator for Health Information Technology. Her responsibilities included supporting the dissemination and adoption of the Bush Administration’s policy on health information technology and the management of the American Health Information Community.
Prior to her position with the Office of the National Coordinator, Ms. Haza was appointed by President Bush to be the Director of the Commission on Systemic Interoperability. Under her direction, the commission report identified the strategy necessary to foster the development of accessible electronic health information to provide optimal health and healthcare for every American.
Prior to her government service, Ms. Haza was the Director of Policy for Newt Gingrich at the American Enterprise Institute and co-authored the book, “Saving Lives & Saving Money,” with Mr. Gingrich and Anne Woodbury. She served on a congressional panel for the AcademyHealth and Friend of AHRQ, and as a consultant to the Gingrich Group and the Center for Health Transformation. While working for Congressman Charlie Norwood (R-GA), she served as Special Projects Director and District Director. She is a graduate of Mercer University, with a degree in journalism.
About Novo Nordisk
Novo Nordisk is a healthcare company with an 80-year history of innovation and achievement in diabetes care. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk’s business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs approximately 22,000 full-time employees in 79 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol “NVO.” For global information, visit http://www.novonordisk.com; for United States information, visit http://www.novonordisk-us.com.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20060418/PHTU019http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comNovo Nordisk
CONTACT: Media: Susan Jackson, +1-609-919-7776, or Investors: MadsVeggerby Lausten, +1-609-919-7937, both of Novo Nordisk
